Posted on 2/7/19
T2 Biosystems Reports Granting of Inducement Awards
LEXINGTON, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical . . .
Posted on 2/7/19
First-of-its-kind Composition Patent Awarded to NED Biosystems for 7-Agent Combination Cancer Therapeutic
NED Biosystems, a clinical-stage biotech company investigating solutions for a range of cancers, today announced that the U.S. Patent and Trademark Office has awarded the company . . .
Posted on 2/7/19
Boston Scientific (BSX) Q4 2018 Earnings Conference Call Transcript
IMAGE SOURCE: THE MOTLEY FOOL.Boston Scientific (NYSE:BSX) Q4 2018 Earnings Conference CallFeb. 6, 2019 8:00 a.m. ETContents:Prepared RemarksQuestions and AnswersCall ParticipantsPrepared Remarks:OperatorLadies and gentlemen, thank you . . .
Posted on 2/6/19
Catabasis Pharmaceuticals Announces Pricing of $20 Million Underwritten Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of an aggregate of 4,000,000 units at . . .
Posted on 2/6/19
Celgene/Bristol-Myers: Analyzing The News Of Starboard's Stake
SummaryIt was reported that Starboard has taken a stake in BMY. The market reaction indicates that investors believe Starboard will advocate against the Celgene acquisition.The Celgene . . .
Posted on 2/6/19
IPO Update: Avedro Files Proposed Terms For IPO
SummaryAvedro aims to raise $75 million from the sale of its common stock in an IPO.The firm is commercializing corneal shaping and repair technologies in the . . .
Posted on 2/6/19
Pulmatrix Closes Public Offering of Common Stock
Pulmatrix, Inc. (NASDAQ: PULM) today announced the closing and funding of its previously announced underwritten public offering of 5,323,530 shares of its common stock at a . . .
Posted on 2/6/19
Pulmatrix Announces 1-for-10 Reverse Stock Split
Pulmatrix, Inc. (NASDAQ: PULM) today announced a 1-for-10 reverse split of its common stock, effective as of 5:00 pm Eastern Time, February 5, 2019. Beginning on February . . .
Posted on 2/6/19
Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it intends to offer its securities in an underwritten public offering. The proposed . . .
Posted on 2/5/19
FEMME Receives Significant Investment from L Catterton Latin America
FEMME – Laboratório da Mulher, a leader in women's healthcare based in São Paulo, today announced a significant investment from the Latin America fund of L . . .
Posted on 2/5/19
Selecta Biosciences Is Worth A Look After Restructuring
SummarySelecta Biosciences enabled a restructuring of its pipeline to save cash and advance its chronic gout drug forward known as SEL-212.By reducing its workforce by 36% . . .
Posted on 2/5/19
3 Stocks Warren Buffett Would Love
When it comes to buy-and-hold investing, no one has done it better than Warren Buffett. Over a timeline that spans more than 50 years, he's compounded . . .
Posted on 2/5/19
Celgene Highlights What Bristol-Myers Squibb Is Getting
Celgene (NASDAQ:CELG) is on track to become part of Bristol-Myers Squibb (NYSE:BMY), but its earnings still matter for current shareholders because the acquisition includes a partial . . .
Posted on 2/5/19
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 11 newly-hired . . .
Posted on 2/5/19
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (“Verastem Oncology” or “the Company”), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, . . .
Posted on 2/4/19
Melinta Therapeutics Provides Corporate Updates
NEW HAVEN, Conn., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics . . .
Posted on 2/4/19
Avedro Launches Initial Public Offering
WALTHAM, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Avedro, Inc., a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision . . .
Posted on 2/4/19
Alexion Reports Fourth Quarter and Full Year 2018 Results
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the fourth quarter and full year of 2018. Total revenues for the full year of . . .
Posted on 2/4/19
The Results Are In, and It's Clear Celgene Doesn't Need Bristol-Myers Squibb
Earnings season is well under way again. Several big drugmakers have already reported their latest quarterly results. Two companies that I was particularly interested in were . . .
Posted on 2/4/19
SIRION Biotech Expands US Presence in Massachusetts
CAMBRIDGE, Mass.--(BUSINESS WIRE)--SIRION Biotech International Inc., a wholly-owned subsidiary of SIRION Biotech GmbH in Germany (“SIRION”), offering the most comprehensive portfolio of custom viral vectors for . . .
Posted on 2/4/19
Dicerna Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board . . .
Posted on 2/4/19
TCR2 Therapeutics Launches Proposed Initial Public Offering
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company developing the next generation of novel T cell receptor therapies for patients suffering from cancer, today announced that it . . .
Posted on 2/1/19
Rhythm Pharmaceuticals: Opportunity To Take Position Ahead Of Pivotal Data
SummaryShares have finished essentially flat since my October 2017 article.I provide a recap of the bullish thesis and recent events.The company's approach to patient identification, establishing . . .
Posted on 2/1/19
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January . . .
Posted on 2/1/19
Pulmatrix Announces Closing of Public Offering of Common Stock
Pulmatrix, Inc. (NASDAQ: PULM) today announced the closing and funding of its previously announced underwritten public offering of 1,561,177 shares of its common stock at a . . .

